FGI-103
Host-Directed Small Molecule With Broad-Spectrum Activity Against Respiratory Viruses
The FGI-103 program is focused upon the development of a broad-spectrum, small molecule inhibitor of human respiratory and hemorrhagic fever viruses. The molecule demonstrates impressive activity against RSV and Ebola viruses in animal models.
The Company intends to submit an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) in 4Q09.
FGI-103 Inhibition of Respiratory Syncytial Virus. Cell-based assays were conducted to evaluate RSV propagation in the presence of FGI-103.
FGI-103 Inhibition of Ebola Virus. Treatment with FGI-103 protected 100% of mice from an otherwise lethal infection with Ebola Virus.